Sep 2019 $3 M No. 8 $2 to $10 million 5
Verax Biomedical Inc.: Raise no. 8, Sep 2019 × Investors in this round 5 investors had bought by the notice of Sep 19, 2019: 5 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $3 M of $11 M offered; $8 M still to sell
Smallest investment taken no minimum stated
What was sold debt, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last more than a year
Issuer's revenue Not disclosed
Sales commissions $425,000
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice James Lousararian · Executive Officer, Director Paul Ragusa · Executive Officer Joe Sanders · Director Marc Goldberg · Director Robert Flanagan · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Four Points Capital Partners LLC (CRD 43149) · broker-dealer Thomas Frederick Zipser (CRD 5248930) · New York, New York Sold in MA Signed by James Lousararian, Chief Executive Officer. Source: SEC Form D, newest notice filed Sep 19, 2019. Read the notice at the SEC .
debt, options SEC Oct 2017 $11 M No. 7 $10 to $50 million 4
Verax Biomedical Inc.: Raise no. 7, Oct 2017 × Investors in this round 4 investors had bought by the notice of Nov 13, 2017: 4 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $11 M of $24 M offered; $13 M still to sell
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice James Lousararian · Executive Officer, Director Joe Sanders · Executive Officer, Director Joe Del Guercio · Director Marc E. Goldberg · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by James Lousararian, Chief executive officer. Source: SEC Form D, newest notice filed Nov 13, 2017. Read the notice at the SEC .
equity, options SEC Feb 2016 $13 M No. 6 $10 to $50 million 64
Verax Biomedical Inc.: Raise no. 6, Feb 2016 × Investors in this round 64 investors had bought by the notice of Jun 27, 2016: 64 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $13 M of $25 M offered; $12 M still to sell
Smallest investment taken no minimum stated
What was sold equity, debt, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice James Lousararian · Executive Officer, Director Joe R. Sanders · Executive Officer, Director Nancy A. Hornbaker · Executive Officer Paul Remo Ragusa · Executive Officer R. Scott Mckenzie · Executive Officer Yli Remo Vallejo · Executive Officer James E. Koziarz · Director Joe Del Guercio · Director Marc E. Goldberg · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by James Lousararian, Chief executive officer. Source: SEC Form D and 1 amendment, newest notice filed Jun 27, 2016. Read the notice at the SEC .
equity, debt, options SEC Jan 2015 $4 M No. 5 $2 to $10 million 61
Verax Biomedical Inc.: Raise no. 5, Jan 2015 × Investors in this round 61 investors had bought by the notice of Jan 21, 2015: 61 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $4 M of $4 M offered
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice James Lousararian · Executive Officer, Director Joe R. Sanders · Executive Officer, Director Nancy A. Hornbaker · Executive Officer Paul Remo Ragusa · Executive Officer R. Scott Mckenzie, Sr. · Executive Officer Yli Remo Vallejo · Executive Officer Buzz Benson · Director James Koziarz · Director Joe Del Guercio · Director Marc Goldberg · Director Robert Zieserl · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by James Lousararian, Chief executive officer. Source: SEC Form D, newest notice filed Jan 21, 2015. Read the notice at the SEC .
equity SEC Jul 2013 $9 M No. 4 $2 to $10 million 83
Verax Biomedical Inc.: Raise no. 4, Jul 2013 × Investors in this round 83 investors had bought by the notice of Oct 15, 2013: 83 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $9 M of $12 M offered; $3 M still to sell
Smallest investment taken no minimum stated
What was sold equity, debt, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Gregory Scott Lawrence · Executive Officer James Lousararian · Executive Officer, Director Joe R. Sanders · Executive Officer, Director Nancy A. Hornbaker · Executive Officer Paul Scott Ragusa · Executive Officer R. Scott Mckenzie, Sr. · Executive Officer Buzz Benson · Director James Koziarz · Director Joe Del Guercio · Director Marc Goldberg · Director Robert Zieserl · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by James Lousararian, Chief executive officer. Source: SEC Form D and 1 amendment, newest notice filed Oct 15, 2013. Read the notice at the SEC .
equity, debt, options SEC Jul 2012 $3 M No. 3 $2 to $10 million 86
Verax Biomedical Inc.: Raise no. 3, Jul 2012 × Investors in this round 86 investors had bought by the notice of Oct 25, 2012: 86 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $3 M of $5 M offered; $2 M still to sell
Smallest investment taken no minimum stated
What was sold debt, options or other rights to buy securities, securities to be acquired by exercising them
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Greg Scott Lawrence · Executive Officer James Lousararian · Executive Officer, Director Joe R. Sanders · Executive Officer, Director Nancy A. Hornbaker · Executive Officer Paul Scott Ragusa · Executive Officer R. Scott Mckenzie · Executive Officer Buzz Benson · Director James Koziarz · Director Joe Del Guercio · Director Marc Goldberg · Director Robert Zieserl · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by James Lousararian, Chief executive officer. Source: SEC Form D and 1 amendment, newest notice filed Oct 25, 2012. Read the notice at the SEC .
debt, options SEC Mar 2011 $1 M No. 2 Under $2 million 26
Verax Biomedical Inc.: Raise no. 2, Mar 2011 × Investors in this round 26 investors had bought by the notice of Mar 22, 2011: 26 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $1 M of $1 M offered
Smallest investment taken no minimum stated
What was sold equity
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice James Lousararian · Executive Officer, Director Joe R. Sanders · Executive Officer, Director Nancy A. Hornbaker · Executive Officer R. Scott Mckenzie · Executive Officer Buzz Benson · Director James Koziarz · Director Joe Del Guercio · Director Marc Goldberg · Director Robert Zieserl · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Paul Ragusa, Vice president, finance & administration. Source: SEC Form D, newest notice filed Mar 22, 2011. Read the notice at the SEC .
equity SEC Apr 2009 $2 M No. 1 $2 to $10 million 12
Verax Biomedical Inc.: Raise no. 1, Apr 2009 × Investors in this round 12 investors had bought by the notice of Apr 15, 2009: 12 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $2 M of $10 M offered; $8 M still to sell
Smallest investment taken no minimum stated
What was sold equity
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in De People named in the notice James Lousararian · Executive Officer, Director Jeffrey A. Hall · Executive Officer Joe R. Sanders · Executive Officer, Director Nancy A. Hornbaker · Executive Officer R. Scott Mckenzie · Executive Officer Buzz Benson · Director James Koziarz · Director Joe DEL GUERCIO · Director Marc Goldberg · Director Robert Zieserl · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by James Lousararian, President. Source: SEC Form D, newest notice filed Apr 15, 2009. Read the notice at the SEC .
equity SEC